MATERIALS TRANSFER AGREEMENT

Provider:
U.S. Environmental Protection Agency (EPA)
Office of Research and Development (ORD)
National Center for Computational Toxicology (NCCT)

Recipient:
Kathy Archibald, Managing Director, Safer Medicines Trust

1. Provider agrees to transfer to Recipient's Investigator named below the following Research Material:

Data and Summary Information
☐ In vitro assay data derived from the ToxCast Program. This data is derived from chemicals analyzed using a variety of high throughput assay techniques. Below this is referred to as the “ToxCast Data”.

Recipient agrees to transfer to the EPA Investigator named below:

☐ Relevant data on these chemicals from non-public sources.

2. This Research Material may not be used in human subjects. The Research Material will be used only for research purposes by Recipient's investigator in his/her laboratory, for the research project described below, under suitable containment conditions. This Research Material will not be used for screening, production or sale, for which a commercialization license may be required. Recipient agrees to comply with all Federal rules and regulations applicable to the Research Project and the handling of the Research Material.

3. Does the Research Material include specimens or data derived or collected from human subjects?
   _____ Yes – Go to item #3(a).
   ☒  No – Skip to item #4.

   3(a). Does the Research Material include specimens or data derived or collected from fetuses, children, pregnant women, or nursing women?
       ______ Yes
       _____ No

   3(b). Was the Research Material obtained under a protocol that was reviewed and
approved by an Institutional Review Board (IRB) that operated in accordance with the requirements of EPA Regulation 40 CFR 26, HHS Regulation 45 CFR 46, or any other Federal Regulation for the protection of human research subjects?

Yes (Please indicate the applicable Regulation here and provide copies of the protocol and IRB approval documents.)

No (Please provide explanation with documentary support as appropriate.)

3(c). Can the Provider of the Research Material identify the subjects directly or through identifiers (codes) linked to the subjects?

Yes – The Recipient’s use of the Research Material may be human subject’s research subject to 40 CFR 26. Go to item #3(d).

No – The Recipient’s use of the Research Material is not human subjects research subject to 40 CFR 26. Skip to item #4.

3(d). Is the Provider of the Research Material prohibited by this agreement from releasing information to the Recipient that might allow the identification of any of the subjects, including but not limited to the key to any existing code?


No – The Recipient’s use of the Research Material may be human subjects research subject to 40 CFR 26. Go to item #3(e).

3(e). Is the Research Material publicly available?

Yes – The Recipient’s use of the Research Material is human subjects research that is exempt from 40 CFR 26.

No – The Recipient’s use of the Research Material is human subjects research that may be subject to 40 CFR 26 and must be further evaluated accordingly by the EPA Human Subjects Review Official.

4. This Research Material will be used by Recipient's investigator solely in connection with the following research project ("Research Project") described with specificity as follows:

Safer Medicines Trust has developed a unique approach to evaluation and qualification of in vitro tests. EPA is conducting a series of ToxCast studies with screening data available for such analysis. EPA will provide chemical screening data from ToxCast to Safer Medicines Trust or its designated affiliate. Safer Medicines Trust or its affiliate will conduct a blinded analysis on chemicals included on the ToxCast chemical list (no chemical transfer is involved). Safer Medicines Trust’s affiliate will have a contract with Safer Medicines Trust and thus will be covered by this MTA. The affiliates that may be involved in analysis and data review and dissemination in close collaboration with EPA are FDA’s Critical Path Institute and National Center of Toxicology Research:
Critical Path Institute
John Michael Sauer, PhD
Executive Director, Predictive Safety Testing Consortium (PSTC)
Critical Path Institute
1730 East River Road
Tucson, AZ 85718-5893
Tele: 520.382.1396
Email: jsauer@c-path.org

and

NCTR/FDA
Weida Tong, Ph.D.
Director,
Division of Bioinformatics and Biostatistics
NCTR/FDA
3900 NCTR Road
Jefferson, AR 72079
Mobile: 501-200-7370
Tele: 870-543-7142
Email: weida.tong@fda.hhs.gov

5. In all oral presentations or written publications concerning the Research Project, Recipient will acknowledge Provider's contribution of this Research Material unless requested otherwise. To the extent permitted by law, Recipient agrees to treat as confidential, any of Provider's written information about this Research Material that is stamped "CONFIDENTIAL" for a period of three (3) years from the date of its disclosure to recipient. The foregoing shall not apply to information that is or becomes publicly available or which is disclosed to Recipient without a confidentiality obligation. Any oral disclosures from Provider to Recipient which Provider wishes to be treated as confidential shall be identified as being Confidential at the time of the disclosure and by written notice delivered to Recipient within thirty (30) days after the date of the oral disclosure. Recipient may publish or otherwise publicly disclose the results of the Research Project, but if Provider has given Confidential information to Recipient, such public disclosure may be made only after Provider has had thirty (30) days to review the proposed disclosure to determine if it includes any Confidential information, to the extent such review period is permitted by law.

6. This Research Material represents a significant investment on the part of Provider and is considered proprietary to Provider. Recipient's investigator therefore agrees to retain control over this Research Material and further agrees not to transfer the Research Material to other people not under his/her direct supervision without advance written approval of Provider. Provider reserves the right to distribute the Research Material to others and to use it for its own
purposes. When the Research Project is completed, the Research Material will be returned to the Provider or disposed, if directed by Provider.

7. This Research Material is provided as a service to the research community. It is being supplied to Recipient with no warranties, express or implied, including any warranty of merchantability or fitness for a particular purpose. Provider makes no representations that the use of the Research Material will not infringe any patent or proprietary rights of third parties.

8. Recipient shall retain title to any patent or other intellectual property rights in inventions made by its employees in the course of the Research Project. However, if said inventions contain any portion of the Research Material, are derived from the Research Material, or could not have been produced but for the use of the Research Material, Recipient agrees to contact the Provider to determine what ownership interests, if any, the Provider may have, and, where applicable, to negotiate in good faith the terms of a commercial license. Inventorship for a patent application or a commercialized product based on said inventions shall be determined according to United States patent law.

9. When Provider is the EPA: Recipient agrees not to claim, infer, or imply endorsement by the Government of the United States of America (hereinafter referred to as "Government") of the Research Project, the institution or personnel conducting the Research Project or any resulting product(s). Recipient agrees to hold the Government harmless and to indemnify the Government for all liabilities, demands, damages, expenses and losses arising out of Recipient's use for any purpose of the Research Material.

10. When Recipient is the EPA: Provider will not be liable to EPA for any claims or damages arising from EPA's use of the Research Material.

11. The Provider shall have the right to terminate this Agreement at any time if Recipient breaches any of the terms of this Agreement. Upon termination, Recipient shall return to the Provider all unused portions of the Research Materials.

12. Will EPA develop any products or services from information or materials provided by the Recipient?

___ Yes – go to item A

X No – skip to #13 (next clause)

Item A: The EPA has a long history of applying principles of quality assurance/quality control to all technical work conducted by or for the Agency (CIO 2106: USEPA Quality Policy). Given EPA is receiving metabolomics and screening data and will use the metabolomics and screening data for Agency purposes, the Recipient is required to provide EPA with documentation such as a quality manual, describing their
organization's quality system. In lieu of such documentation, Standard Operating
Protocols for compound handling and the assays performed are acceptable or
documentation showing third party accreditation to a relevant standard and scope is also
acceptable for documenting an organization's quality system. EPA requirements for
quality management plans can be found at this URL:
http://www.epa.gov/quality/qa_docs.html

13. All notices pertaining to or required by this Agreement shall be in writing and shall be
signed by an authorized representative and shall be delivered by hand (including private courier
mail service) or sent by certified mail, return receipt requested, with postage prepaid, addressed
as follows:

Provider's Contact Information:

Russell Thomas, Director
National Center for Computational Toxicology (NCCT)
US EPA
109 TW Alexander (MD-B-205-01)
Research Triangle Park, NC 27711
Tele: 919-541-5776
Email: Thomas.russell@epa.gov

With copy to:
Sandra Roberts, Acting Associate Director
National Center for Computational Toxicology (NCCT)
US EPA
109 TW Alexander (MD-B-205-01)
Research Triangle Park, NC 27711
Tele: 919-541-3850
Email: Roberts.sandra@epa.gov

For commercial courier address use:
4930 Old Page Rd.
Durham, NC 27703
Recipient's Contact Information:

Kathy Archibald, Managing Director
Safer Medicines Trust
PO Box 122
Kingsbridge, TQ7 9AX
United Kingdom
Tele: +44-(0)30-0302-0521
Email: Kathy@safermedicines.org

With copy to:
Katya Tsaoun, Ph.D.
Scientific Director, US
Safer Medicines Trust
PO Box 122
Kingsbridge, TQ7 9AX
United Kingdom
Tele: 508-812-0850
Email: katya@safermedicines.org

14. Paragraphs 2, 7, 9 and 10 shall survive termination.

15. This Agreement shall be construed in accordance with law as applied by the Federal courts in the District of Columbia.

16. The undersigned Provider and Recipient expressly certify and affirm that the contents of any statements made herein are truthful and accurate.

17. This agreement shall enter into force as of the date of the last signature of the parties and shall remain in effect for one year from said date.
Any false or misleading statements made, presented, or submitted to the Government, including any material omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including 31 U.S.C. § 3801-3812 (civil liability), 18 U.S.C. § 1001 (criminal liability), and 31 U.S.C. § 3729-33 (False Claims Act).